Home > News & Opinion > In Brief > 2011 > Molecular mechanisms: Placenta influences brain development

Molecular mechanisms: Placenta influences brain development

Popularity tracker
Jessica Wright
31 May 2011

Crucial chemical: Serotonin, a neurotransmitter implicated in mental illness, is involved in fetal brain development.

The placenta regulates the levels of the neurotransmitter serotonin in the brains of mice at a key stage in embryonic development, according to a study published 21 April in Nature1. The results suggest that the fetal environment can influence the long-term mental health of children, including whether they later develop autism or schizophrenia.

Several studies have linked serotonin — a chemical messenger implicated in depression and anxiety — to autism. High levels of serotonin in the blood and lower activity in the brain of a transporter that regulates serotonin levels are both associated with the disorder. Studies have also suggested that variations in the serotonin transporter gene in the mother can influence the development of autism in the offspring.

Previous studies have suggested that embryos are exposed to serotonin through the mother's blood. The new study rules this out by showing that mouse embryos at day 12 have typical brain levels of serotonin, even when their mothers have a mutation in the serotonin transporter that virtually eliminates it from maternal blood.

Instead, the study concludes that the placenta itself produces serotonin. When tryptophan — an amino acid that is a precursor for serotonin — is injected into an artery that feeds the placenta, brain levels of serotonin in the embryo rise. By contrast, injecting the mother with serotonin does not raise its levels in the fetal brain.

Studies have associated mutations in an enzyme involved in tryptophan metabolism, called TDO2, with autism2.

This article has been modified from the original. It has been changed to correct the role of the TDO2 enzyme.

References:

  1. Bonnin et al. Nature 472, 347-350 (2011) PubMed

  2. Nabi et al. Am. J. Med. Genet. B Neuropsychiatr. Genet. 125, 63-68 (2004) PubMed

Comments

Name: Ken Aitken
31 May 2011 - 11:26AM

TDO2 is a rate-limiting enzyme in the pathway that uses tryptophan in the production of kynurenine,and has been implicated in a small number of ASD cases. It is not involved in tryptophan production, but like the enzymes involved in the pathway from tryptophan through 5HTP, serotonin, N-Acetylserotonin to melatonin is involved in its metabolism.

Name: Jessica Wright
31 May 2011 - 4:44PM

Dear Ken,

We have adjusted the article to reflect your clarification on the role of TDO2.

Thank you for your careful reading of SFARI!

Name: Best mattress
2 December 2011 - 6:09AM

I suggest adding a "google+" button for the blog!

Add a Comment

You can add a comment by filling out the form below. Plain text formatting.

Question: What is 10 + 4 ?
Your answer: